Back to Main

Faculty Detail    
Name MIN XIE
Assistant Professor, Division of Cardiovascular Disease
 
Campus Address MCLM 297 Zip 0005
Phone
E-mail
Other websites
     

Education
Medical School  Medical School, Shandong University, Jinan, Shandong, China    1995  MD, MSci 
Graduate  Baylor College of Medicine, Houston, TX    2004  PhD 
Residency  UT Southwestern Medical Center, Dallas, TX    2010  Internal Medicine 
Fellowship  UT Southwestern Medical Center, Dallas, TX    2015  Cardiology  

Certifications
Internal Medicine Board Certification  2010 
Internal Medicine Board Certification-Cardiovascular Diseases   2015 


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Medicine  Med - Cardiovascular Disease Assistant Professor
Center  Comprehensive Cardiovascular Ctr  Comprehensive Cardiovascular Ctr Assistant Professor
Center  Comprehensive Diabetes Center  Comprehensive Diabetes Center Assistant Professor

Graduate Biomedical Sciences Affiliations
Waiting to be Seated 

Biographical Sketch 
Dr. Xie is an Assistant Professor of Medicine in the Division of Cardiovascular Disease. Dr Xie obtained his MD at Shandong University, graduating with honors. With his interested in the molecular mechanisms of heart disease, Dr. Xie joined the Ph.D. program at Baylor College of Medicine. Dr. Xie studied mitogen activated protein kinases (MAPK) pathway, specifically “the Role of TAK1 and its Activator, HGK, in Cardiomyocyte Survival and Cardiac Development”. These studies led to multiple publications. The TAK1 floxed allele that Dr. Xie generated has been distributed to multiple researchers for their studies in systems other than heart and has led to 8 high quality publications with Dr. Xie as coauthor. Dr. Xie has a strong desire to couple clinical practice with fundamental and translational research. He matched at UT Southwestern for clinical training in Internal Medicine, followed by Cardiology training. During his Cardiology Fellowship, Dr. Xie have found that SAHA, a FDA-approved anti-cancer HDAC inhibitor, reduced infarct size by 40% when given at the time of reperfusion in a rabbit I/R model (large animal model). Mechanistically, SAHA induces autophagy in the infarct border zone to prevent cardiomyocyte death. This work in various forms has been presented at AHA, ACC, HFSA and Northwestern Cardiovascular Young Investigators' Forum and Dr. Xie have won two awards. This study has led to a recent Circulation publication. After his graduation, Dr. Xie joined UAB faculty in Aug 2015. Dr. Xie is dedicated to build a career as a physician-scientist in the area of heart failure mechanisms and novel therapeutics, concentrating on mitigating ischemia-reperfusion injury and adverse remodeling. Dr. Xie is dedicated toward both teaching residents in the CCU and research in his lab. Dr. Xie’s aspiration is to combine his areas of interest -- cardiac research and cardiac patient care -- believing firmly that each will strengthen his ability to perform the other.

Society Memberships
Organization Name Position Held Org Link
American College of Cardiology   2010   
American Heart Association  2000   



Research/Clinical Interest
Title
Autophagy-dependent cardioprotection in ischemia/reperfusion injury
Description
Dr. Xie's clinical interest is general cardiology, focusing on echocardiography. His research interest is the molecular mechanism of heart failure and novel therapeutics, concentrating on mitigating ischemia/reperfusion injury and adverse remodeling.

Selected Publications 
Publication PUBMEDID
Xie M, Kong Y, Tan W, May H, Battiprolu PK, Pedrozo Z, Wang Z, Morales C, Luo X, Cho G, Jiang N, Jessen ME, Warner JJ, Lavandero S, Gillette TG, Turer AT, Hill JA. (2014) HDAC Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy. Circulation.2014, Mar 11;129(10):1139-51. doi:10.1161/CIRCULATIONAHA.113.002416. Epub 2014 Jan 6.  24396039 
Greenblatt, M. B., Shim, J. H., Zou, W., Sitara, D., Schweitzer, M., Hu, D., Lotinun, S., Sano, Y., Baron, R., Park, J. M., Arthur, S., Xie, M., Schneider, M. D., Zhai, B., Gygi, S., Davis, R., and Glimcher, L. H. (2010) The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice, J Clin Invest 120, 2457-2473.   20551513 
Fan, Y., Yu, Y., Shi, Y., Sun, W., Xie, M., Ge, N., Mao, R., Chang, A., Xu, G., Schneider, M. D., Zhang, H., Fu, S., Qin, J., and Yang, J. (2010) Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha- and interleukin-1beta-induced IKK/NF-kappaB and JNK/AP-1 activation, J Biol Chem 285, 5347-5360.  20038579  
Shim, J. H., Greenblatt, M. B., Xie, M., Schneider, M. D., Zou, W., Zhai, B., Gygi, S., and Glimcher, L. H. (2009) TAK1 is an essential regulator of BMP signalling in cartilage, EMBO J 28, 2028-2041.   19536134 
Yu, Y., Ge, N., Xie, M., Sun, W., Burlingame, S., Pass, A. K., Nuchtern, J. G., Zhang, D., Fu, S., Schneider, M. D., Fan, J., and Yang, J. (2008) Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression, J Biol Chem 283, 24497-24505.   18617512  
Chang J, Xie M, Shah VR, Schneider MD, Entman ML, Wei L, et al. (2006) Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis, Proc Natl Acad Sci U S A 103, 14495-14500.   16983089 
Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini A, Khoury DS, Schneider MD. Transforming growth factor beta-activated kinase-1 modulates the energy-sensor pathway for Wolff-Parkinson-White syndrome. Proc Natl Acad Sci USA. 2006 Nov 14;103(46):17378-17383.  17085580  
Liu, H. H., Xie, M., Schneider, M. D., and Chen, Z. J. (2006) Essential role of TAK1 in thymocyte development and activation, Proc Natl Acad Sci U S A 103, 11677-11682.   16857737 
Wan, Y. Y., Chi, H., Xie, M., Schneider, M. D., and Flavell, R. A. (2006) The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function, Nat Immunol 7, 851-858.  16799562 
Xie M, Burchfield JS, Hill JA. Pathological ventricular remodeling: therapies: part 2 of 2. Circulation. 2013 Aug 27;128(9):1021-30. doi: 10.1161/CIRCULATIONAHA.113.001879. Review  23979628 
Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: therapies: part 1 of 2. Circulation. 2013 Jul 23;128(4):388-400. doi: 10.1161/CIRCULATIONAHA.113.001878. Review  23877061 
Xie M, Hill JA. HDAC-dependent ventricular remodeling. Trends Cardiovasc Med. 2013 Aug;23(6):229-35. doi: 10.1016/j.tcm.2012.12.006. Epub 2013 Mar 15. Review  23499301  
Xie M, Morales CR, Lavandero S, Hill JA. Tuning flux: autophagy as a target of heart disease therapy. Curr Opin Cardiol. 2011 May;26(3):216-22. doi: 10.1097/HCO.0b013e328345980a. Review  21415729 

Keywords
heart failure, ischemia/reperfusion injury, autophagy